FDA Removes Black Box Warnings on Hormone Replacement Therapy
1 report, 1 independent
Updated Mon 00:00
AI-generated briefing. Brind wrote this from the reports listed below. It can be wrong. Each section says how much you can rely on it, and the sources are linked so you can check.
What happened
The U.S. Department of Health and Human Services announced the removal of broad black box warnings from Hormone Replacement Therapy products for menopause on November 2, 2026. The FDA had initiated the removal of these warnings in November 2025.
From targetednews.com
Why it matters
This regulatory action by the FDA changes the labeling requirements for Hormone Replacement Therapy. The change relates to ongoing discussions regarding regulatory actions concerning hormone therapy.
Einhorn discusses regulatory actions regarding hormone therapy with the FDA.
From targetednews.com
Who's involved
- FDARegulatory agency that removed the black box warnings on Hormone Replacement Therapy
Keep exploring
The entities involved
Related events
- Dorothy Fink discussed FDA policy changes concerning estrogen, which was reported by USA Today.
- The FDA reviewed risks and loosened the label on testosterone replacement therapy (TRT) following an attempt by the Trump administration to reverse its decline.
- The FDA requested additional clinical data from Unicycive Therapeutics.